The next-generation oncology devices and solutions market size has grown rapidly in recent years. It will grow from $16.41 billion in 2025 to $19.46 billion in 2026 at a compound annual growth rate (CAGR) of 18.6%. The growth in the historic period can be attributed to increasing global cancer incidence rates, expansion of molecular diagnostic capabilities, availability of advanced oncology testing tools, growth of hospital-based cancer care programs, rising adoption of targeted therapies.
The next-generation oncology devices and solutions market size is expected to see rapid growth in the next few years. It will grow to $38.19 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to increasing demand for personalized cancer treatment, rising investments in genomic diagnostics, expansion of early screening programs, growing integration of ai in oncology workflows, advancements in biomarker-based cancer management. Major trends in the forecast period include increasing adoption of precision oncology platforms, rising use of ngs-based cancer diagnostics, growing integration of digital pathology solutions, expansion of personalized cancer treatment approaches, enhanced focus on early detection technologies.
The growing prevalence of cancer is expected to drive the expansion of the next-generation oncology devices and solutions market. Cancer is a disease characterized by uncontrolled growth of abnormal cells, which can spread to other areas of the body, disrupting normal functions. The increasing prevalence of cancer is mainly due to aging populations, as the risk of developing cancer rises with age. Next-generation oncology devices and solutions help address this rise by enabling earlier detection, more accurate diagnosis, and personalized treatment. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, estimated that cancer would cause over 611,000 deaths in the United States, which equals more than 1,600 cancer-related deaths per day. As such, the growing prevalence of cancer is a key driver for the growth of the next-generation oncology devices and solutions market.
Leading companies in the next-generation oncology devices and solutions market are focusing on technological innovations, such as next-generation sequencing (NGS) target enrichment solutions, to improve the detection of rare genetic variants, enhance sequencing accuracy, and expedite cancer diagnosis and treatment decisions. NGS target enrichment solutions involve techniques that selectively capture and concentrate specific DNA or RNA regions for sequencing, allowing more precise and efficient analysis of genetic variants associated with cancer and other diseases. For instance, in April 2025, Integrated DNA Technologies (IDT), a US-based biotechnology company, launched the xGen Hybridization and Wash v3 Kit, an advanced hybridization capture solution designed to accelerate cancer research by streamlining NGS workflows. This kit reduces hybridization time to just one hour, enabling researchers to complete sample preparation and sequencing in a single workday. By eliminating the need for heated buffers and cutting hands-on time by 20%, the solution is highly automation-friendly and ideal for high-throughput applications.
In July 2024, Hologic, a US-based medical technology company, acquired Endomag for an undisclosed amount. This acquisition aims to enhance Hologic's breast cancer surgery portfolio by incorporating Endomag's innovative surgical guidance products, which improve the precision and effectiveness of cancer care. Endomag, a UK-based medical device manufacturer, specializes in surgical guidance products for breast cancer treatment.
Major companies operating in the next-generation oncology devices and solutions market are Johnson & Johnson Services Inc., Siemens AG, Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Elekta AB, Myriad Genetics Inc., Takara Bio USA Inc., NeoGenomics Inc., Guardant Health Inc., Accuray Incorporated, SOPHiA GENETICS SA, Paige.AI Inc., Deep Bio Inc., Lucida Medical Ltd.
North America was the largest region in the next-generation oncology devices and solutions market in 2025. The regions covered in the next-generation oncology devices and solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation oncology devices and solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the next-generation oncology devices and solutions market by increasing costs of imported sequencing equipment, diagnostic reagents, imaging systems, electronic components, and precision manufacturing tools. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported advanced technologies, while Asia-Pacific faces pricing pressure on oncology device exports. These tariffs are raising testing and equipment costs and influencing procurement timelines. At the same time, they are encouraging domestic manufacturing, regional R&D investments, and local production of oncology diagnostic and therapeutic solutions.
The next-generation oncology devices and solutions market research report is one of a series of new reports that provides next-generation oncology devices and solutions market statistics, including next-generation oncology devices and solutions industry global market size, regional shares, competitors with a next-generation oncology devices and solutions market share, detailed next-generation oncology devices and solutions market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation oncology devices and solutions industry. This next-generation oncology devices and solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation oncology devices and solutions encompass advanced technologies and tools developed to detect, diagnose, monitor, and treat various forms of cancer with enhanced precision and speed. Their goal is to facilitate personalized cancer care by utilizing innovations such as next-generation sequencing, digital pathology, and targeted therapies to improve patient outcomes.
The primary cancer types addressed by next-generation oncology devices and solutions include breast cancer, cervical cancer, colorectal cancer, and lung cancer. Breast cancer is a condition where cells in the breast grow uncontrollably, often forming a tumor that can be felt as a lump or identified through imaging. These solutions employ technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), DNA microarrays, multiplexing, and other advanced techniques, which are applied in areas such as screening and early detection, prognostics and monitoring, therapy selection, and recurrence monitoring. The key end users include hospitals and clinics, diagnostic laboratories, academic and research institutions, and more.
The next-generation oncology devices and solutions market consists of revenues earned by entities by providing services such as cancer genomic profiling and sequencing, personalized treatment planning, remote patient monitoring and tele-oncology, and early cancer detection and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation oncology devices and solutions market also includes sales of liquid biopsy kits, companion diagnostic tests, digital pathology systems, cancer biomarker detection assays, and targeted therapy monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The next-generation oncology devices and solutions market size is expected to see rapid growth in the next few years. It will grow to $38.19 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to increasing demand for personalized cancer treatment, rising investments in genomic diagnostics, expansion of early screening programs, growing integration of ai in oncology workflows, advancements in biomarker-based cancer management. Major trends in the forecast period include increasing adoption of precision oncology platforms, rising use of ngs-based cancer diagnostics, growing integration of digital pathology solutions, expansion of personalized cancer treatment approaches, enhanced focus on early detection technologies.
The growing prevalence of cancer is expected to drive the expansion of the next-generation oncology devices and solutions market. Cancer is a disease characterized by uncontrolled growth of abnormal cells, which can spread to other areas of the body, disrupting normal functions. The increasing prevalence of cancer is mainly due to aging populations, as the risk of developing cancer rises with age. Next-generation oncology devices and solutions help address this rise by enabling earlier detection, more accurate diagnosis, and personalized treatment. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization, estimated that cancer would cause over 611,000 deaths in the United States, which equals more than 1,600 cancer-related deaths per day. As such, the growing prevalence of cancer is a key driver for the growth of the next-generation oncology devices and solutions market.
Leading companies in the next-generation oncology devices and solutions market are focusing on technological innovations, such as next-generation sequencing (NGS) target enrichment solutions, to improve the detection of rare genetic variants, enhance sequencing accuracy, and expedite cancer diagnosis and treatment decisions. NGS target enrichment solutions involve techniques that selectively capture and concentrate specific DNA or RNA regions for sequencing, allowing more precise and efficient analysis of genetic variants associated with cancer and other diseases. For instance, in April 2025, Integrated DNA Technologies (IDT), a US-based biotechnology company, launched the xGen Hybridization and Wash v3 Kit, an advanced hybridization capture solution designed to accelerate cancer research by streamlining NGS workflows. This kit reduces hybridization time to just one hour, enabling researchers to complete sample preparation and sequencing in a single workday. By eliminating the need for heated buffers and cutting hands-on time by 20%, the solution is highly automation-friendly and ideal for high-throughput applications.
In July 2024, Hologic, a US-based medical technology company, acquired Endomag for an undisclosed amount. This acquisition aims to enhance Hologic's breast cancer surgery portfolio by incorporating Endomag's innovative surgical guidance products, which improve the precision and effectiveness of cancer care. Endomag, a UK-based medical device manufacturer, specializes in surgical guidance products for breast cancer treatment.
Major companies operating in the next-generation oncology devices and solutions market are Johnson & Johnson Services Inc., Siemens AG, Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Elekta AB, Myriad Genetics Inc., Takara Bio USA Inc., NeoGenomics Inc., Guardant Health Inc., Accuray Incorporated, SOPHiA GENETICS SA, Paige.AI Inc., Deep Bio Inc., Lucida Medical Ltd.
North America was the largest region in the next-generation oncology devices and solutions market in 2025. The regions covered in the next-generation oncology devices and solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation oncology devices and solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the next-generation oncology devices and solutions market by increasing costs of imported sequencing equipment, diagnostic reagents, imaging systems, electronic components, and precision manufacturing tools. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported advanced technologies, while Asia-Pacific faces pricing pressure on oncology device exports. These tariffs are raising testing and equipment costs and influencing procurement timelines. At the same time, they are encouraging domestic manufacturing, regional R&D investments, and local production of oncology diagnostic and therapeutic solutions.
The next-generation oncology devices and solutions market research report is one of a series of new reports that provides next-generation oncology devices and solutions market statistics, including next-generation oncology devices and solutions industry global market size, regional shares, competitors with a next-generation oncology devices and solutions market share, detailed next-generation oncology devices and solutions market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation oncology devices and solutions industry. This next-generation oncology devices and solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation oncology devices and solutions encompass advanced technologies and tools developed to detect, diagnose, monitor, and treat various forms of cancer with enhanced precision and speed. Their goal is to facilitate personalized cancer care by utilizing innovations such as next-generation sequencing, digital pathology, and targeted therapies to improve patient outcomes.
The primary cancer types addressed by next-generation oncology devices and solutions include breast cancer, cervical cancer, colorectal cancer, and lung cancer. Breast cancer is a condition where cells in the breast grow uncontrollably, often forming a tumor that can be felt as a lump or identified through imaging. These solutions employ technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), DNA microarrays, multiplexing, and other advanced techniques, which are applied in areas such as screening and early detection, prognostics and monitoring, therapy selection, and recurrence monitoring. The key end users include hospitals and clinics, diagnostic laboratories, academic and research institutions, and more.
The next-generation oncology devices and solutions market consists of revenues earned by entities by providing services such as cancer genomic profiling and sequencing, personalized treatment planning, remote patient monitoring and tele-oncology, and early cancer detection and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation oncology devices and solutions market also includes sales of liquid biopsy kits, companion diagnostic tests, digital pathology systems, cancer biomarker detection assays, and targeted therapy monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Next-Generation Oncology Devices and Solutions Market Characteristics
3. Next-Generation Oncology Devices and Solutions Market Supply Chain Analysis
4. Global Next-Generation Oncology Devices and Solutions Market Trends and Strategies
5. Next-Generation Oncology Devices and Solutions Market Analysis of End Use Industries
7. Global Next-Generation Oncology Devices and Solutions Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Next-Generation Oncology Devices and Solutions Total Addressable Market (TAM) Analysis for the Market
9. Next-Generation Oncology Devices and Solutions Market Segmentation
10. Next-Generation Oncology Devices and Solutions Market Regional and Country Analysis
11. Asia-Pacific Next-Generation Oncology Devices and Solutions Market
12. China Next-Generation Oncology Devices and Solutions Market
13. India Next-Generation Oncology Devices and Solutions Market
14. Japan Next-Generation Oncology Devices and Solutions Market
15. Australia Next-Generation Oncology Devices and Solutions Market
16. Indonesia Next-Generation Oncology Devices and Solutions Market
17. South Korea Next-Generation Oncology Devices and Solutions Market
18. Taiwan Next-Generation Oncology Devices and Solutions Market
19. South East Asia Next-Generation Oncology Devices and Solutions Market
20. Western Europe Next-Generation Oncology Devices and Solutions Market
21. UK Next-Generation Oncology Devices and Solutions Market
22. Germany Next-Generation Oncology Devices and Solutions Market
23. France Next-Generation Oncology Devices and Solutions Market
24. Italy Next-Generation Oncology Devices and Solutions Market
25. Spain Next-Generation Oncology Devices and Solutions Market
26. Eastern Europe Next-Generation Oncology Devices and Solutions Market
27. Russia Next-Generation Oncology Devices and Solutions Market
28. North America Next-Generation Oncology Devices and Solutions Market
29. USA Next-Generation Oncology Devices and Solutions Market
30. Canada Next-Generation Oncology Devices and Solutions Market
31. South America Next-Generation Oncology Devices and Solutions Market
32. Brazil Next-Generation Oncology Devices and Solutions Market
33. Middle East Next-Generation Oncology Devices and Solutions Market
34. Africa Next-Generation Oncology Devices and Solutions Market
36. Next-Generation Oncology Devices and Solutions Market Competitive Landscape and Company Profiles
37. Next-Generation Oncology Devices and Solutions Market Other Major and Innovative Companies
40. Next-Generation Oncology Devices and Solutions Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Next-Generation Oncology Devices And Solutions Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses next-generation oncology devices and solutions market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for next-generation oncology devices and solutions? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation oncology devices and solutions market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Cancer Type: Breast Cancer; Cervical Cancer; Colorectal Cancer; Lung Cancer2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); DNA Microarrays; Multiplexing; Other Technologies
3) By Application: Screening And Early Detection; Prognostics And Monitoring; Therapy Selection; Recurrence Monitoring; Other Applications
4) By End Use: Hospitals And Clinics; Diagnostic Laboratories; Academic And Research Institutions; Other End Uses
Subsegments:
1) By Breast Cancer: Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer2) By Cervical Cancer: Squamous Cell Carcinoma; Adenocarcinoma; Adenosquamous Carcinoma
3) By Colorectal Cancer: Colon Cancer; Rectal Cancer; Metastatic Colorectal Cancer
4) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC); Lung Adenocarcinoma; Squamous Cell Lung Carcinoma
Companies Mentioned: Johnson & Johnson Services Inc.; Siemens AG; Merck & Co. Inc.; Thermo Fisher Scientific Inc.; Novartis AG; Koninklijke Philips N.V.; GE HealthCare Technologies Inc.; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; QIAGEN N.V.; Exact Sciences Corporation; Elekta AB; Myriad Genetics Inc.; Takara Bio USA Inc.; NeoGenomics Inc.; Guardant Health Inc.; Accuray Incorporated; SOPHiA GENETICS SA; Paige.AI Inc.; Deep Bio Inc.; Lucida Medical Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Next-Generation Oncology Devices and Solutions market report include:- Johnson & Johnson Services Inc.
- Siemens AG
- Merck & Co. Inc.
- Thermo Fisher Scientific Inc.
- Novartis AG
- Koninklijke Philips N.V.
- GE HealthCare Technologies Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- Sysmex Corporation
- QIAGEN N.V.
- Exact Sciences Corporation
- Elekta AB
- Myriad Genetics Inc.
- Takara Bio USA Inc.
- NeoGenomics Inc.
- Guardant Health Inc.
- Accuray Incorporated
- SOPHiA GENETICS SA
- Paige.AI Inc.
- Deep Bio Inc.
- Lucida Medical Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 19.46 Billion |
| Forecasted Market Value ( USD | $ 38.19 Billion |
| Compound Annual Growth Rate | 18.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
